8 reports

  • 7.5 STRATEGIES TO ENSURE LONG-TERM COMPLIANCE IN IMMUNOTHERAPY PROTOCOLS
  • 7.3.2 BIOMARKERS TO BETTER EVALUATE PATIENT RESPONSES TO IMMUNOTHERAPY TREATMENT

ONE OF THE MAIN BARRIERS TO THE SUCCESS OF PEANUT IMMUNOTHERAPIES THERAPIES IS THE QUESTION OF HOW THEY WILL BE REIMBURSED.

  • Allergy
  • Immunotherapy
  • Australasia
  • Australia
  • Aimmune Therapeutics, Inc.
  • December 17, 2015
  • YERVOY SWOT ANALYSIS, 2017

JOURNAL OF IMMUNOTHERAPY; ##(##): ##-##.

  • Immunotherapy
  • Australasia
  • Oceania
  • Merck & Co., Inc.
  • Novartis AG
  • 10/17/2017: IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2017 ANNUAL MEETING
  • MAR 21, 2018: IMMUTEP COMMENCES PATIENT DOSING IN ADDITIONAL TACTI-MEL COHORT

" As advancements in PD-## have enabled breakthroughs in immunotherapy, research is showing that LAG-## has the potential to take immunotherapy to the next level, enabling more effective cancer treatments.

  • Clinical Trial
  • Immunotherapy
  • Therapy
  • Australasia
  • Immutep SA
  • 10/17/2017: IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2017 ANNUAL MEETING
  • MAR 21, 2018: IMMUTEP COMMENCES PATIENT DOSING IN ADDITIONAL TACTI-MEL COHORT

" As advancements in PD-## have enabled breakthroughs in immunotherapy, research is showing that LAG-## has the potential to take immunotherapy to the next level, enabling more effective cancer treatments.

  • Clinical Trial
  • Immunotherapy
  • Therapy
  • Australasia
  • Immutep SA
  • Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline with Acceptance Of Regulatory Submission And New Market Approval

THE DRUG CANDIDATE IS AN IMMUNOTHERAPY.

  • Allergy Drug
  • Allergy Immunotherapy
  • Immunotherapy
  • Australasia
  • Product Initiative
  • 10/17/2017: IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2017 ANNUAL MEETING
  • MAR 21, 2018: IMMUTEP COMMENCES PATIENT DOSING IN ADDITIONAL TACTI-MEL COHORT

" As advancements in PD-## have enabled breakthroughs in immunotherapy, research is showing that LAG-## has the potential to take immunotherapy to the next level, enabling more effective cancer treatments.

  • Clinical Trial
  • Immunotherapy
  • Therapy
  • Australasia
  • Immutep SA

This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation, said William J.

  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • Australasia
  • Product Initiative
  • PMC-201 - DRUG PROFILE

DURING THE OPTIMIZING COMBINATION IMMUNOTHERAPY SESSION.

  • Immunotherapy
  • Lung Cancer
  • Australasia
  • Product Initiative
  • OncoMed Pharmaceuticals, Inc.